HSCS — Heart Test Laboratories Income Statement
0.000.00%
- $2.39m
- -$4.19m
- $0.01m
- 26
- 30
- 24
- 16
Annual income statement for Heart Test Laboratories, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0.064 | 0.026 | 0.014 | 0.005 |
Cost of Revenue | ||||
Gross Profit | 0.018 | 0.015 | 0.006 | 0.002 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 3.87 | 2.34 | 4.47 | 6.12 |
Operating Profit | -3.81 | -2.32 | -4.46 | -6.11 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -3.81 | -2.45 | -4.83 | -6.35 |
Net Income After Taxes | -3.81 | -2.45 | -4.83 | -6.35 |
Net Income Before Extraordinary Items | ||||
Net Income | -3.81 | -2.45 | -4.83 | -6.35 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Dilution Adjustment | ||||
Diluted Net Income | -3.81 | -2.45 | -4.83 | -6.35 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.475 | -0.336 | -0.617 | -0.799 |
Dividends per Share |